Fig. 4

ATOR-1015 induces anti-tumor responses and immunological memory. Female hOX40tg mice were inoculated with MB49 cells day 0 and treated with indicated doses of ATOR-1015, monotargeting anti-CTLA-4 and anti-OX40 antibodies or vehicle day 7, 10 and 13 followed by monitoring of tumor volume and survival. (a, b) Tumor volume and survival of homozygous mice given vehicle or different doses of ATOR-1015 (n = 18–19). (c, d) Tumor growth and survival in heterozygous mice treated with ATOR-1015, anti-CTLA-4, anti-OX40 antibodies (248 μg for bsAbs or 200 μg for mAbs) or vehicle (n = 10). (e) Complete responders after treatment with ATOR-1015 as described above were re-exposed with MB49 tumor cells to demonstrate immunological memory. Naïve mice were included as tumor growth controls (n = 5). (f) Complete responders after treatment with ATOR-1015 as described above were re-exposed in a twin tumor model with the specific tumor (MB49) in one flank and an irrelevant tumor (PANC02) in the other to demonstrated tumor-specific memory (n = 6). All data is presented as mean ± SEM. Tumor volume was analyzed using Mann-Whitney, two-tailed test and survival using Kaplan-Meier, Log-Rank (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). n equals the number of mice